Health Care Stocks Play Prominent Roles in Steven Romick's Transactions

Guru reduces stakes in CVS Health, Express Scripts, Thermo Fisher in 3rd quarter

Dec 15, 2015

The health care sector occupies a low position in Steven Romick (Trades, Portfolio)’s sector weightings, but those companies were among his most prominent third-quarter trades.

Romick’s most noteworthy third-quarter transaction was the reduction of his stake in CVS Health Corp. (CVS, Financial), a Woonsocket, Rhode Island-based health care company, by nearly 88%. Romick sold 3,639,490 shares for an average price of $105.29 per share. The deal had a -3.68% impact on Romick’s portfolio.

CVS Health has a market cap of $104.21 billion and an enterprise value of $128.43 billion. It has a P/E of 21.2, a forward P/E of 16.1, a P/B of 2.8 and a P/S of 0.7. GuruFocus has given CVS Health a Financial Strength rating of 8/10 and a Profitability and Growth rating of 8/10.

CVS Health sold for $94.11 per share Monday.

Romick reduced his stake in Express Scripts Holding Co. (ESRX, Financial), a St. Louis-based health care and pharmaceutical company, by more than 68%. Romick sold 2,904,380 shares for an average price of $87.1 per share. The transaction had a -2.48% impact on Romick’s portfolio.

Express Scripts Holding has a market cap of $58.04 billion and an enterprise value of $73.29 billion. It has a P/E of 26.6, a forward P/E of 14.1, a P/B of 3.5 and a P/S of 0.6. GuruFocus has given Express Scripts Holding a Financial Strength rating of 7/10 and a Profitability and Growth rating of 8/10.

On Monday Express Scripts Holding sold for $85.82 per share.

Romick reduced his stake in Thermo Fisher Scientific Inc. (TMO, Financial), a Waltham, Massachusetts-based laboratory equipment company, by more than 44%. Romick sold 1,405,300 shares for an average price of $130.28 per share. The deal had a -1.75% impact on Romick’s portfolio.

Thermo Fisher Scientific has a market cap of $54.04 billion and an enterprise value of $66.85 billion. It has a P/E of 27.7, a forward P/E of 16.0, a P/B of 2.6 and a P/S of 3.2. GuruFocus has given Thermo Fisher Scientific a Financial Strength rating of 7/10 and a Profitability and Growth rating of 9/10.

Thermo Fisher Scientific sold for $135.41 per share Monday.

Romick increased his stake in United Technologies Corp. (UTX, Financial), a Hartford, Connecticut-based technology conglomerate, by nearly 178%. Romick acquired 3,342,610 shares for an average price of $97.82 per share. The transaction had a 3.18% impact on Romick’s portfolio.

United Technologies has a market cap of $82.52 billion and an enterprise value of $101.24 billion. It has a P/E of 14.4, a forward P/E of 14.0, a P/B of 2.7 and a P/S of 1.3. GuruFocus has given United Technologies a Financial Strength rating of 7/10 and a Profitability and Growth rating of 8/10.

On Monday United Technologies sold for $93.03 per share.

Romick raised his stake in Alcoa Inc. (AA, Financial), a New York-based metals and manufacturing company, by nearly 36%. Romick purchased 10,932,342 shares for an average price of $9.74 per share. The deal had a 1.13% impact on Romick’s portfolio.

Alcoa has a market cap of $11.79 billion and an enterprise value of $21.48 billion. It has a P/E of 23.0, a forward P/E of 16.5, a P/B of 0.9 and a P/S of 0.5. GuruFocus has given Alcoa a Financial Strength rating of 6/10 and a Profitability and Growth rating of 6/10.

Seth Klarman (Trades, Portfolio), First Pacific Advisors (Trades, Portfolio), Manning & Napier Advisors Inc., Mario Gabelli (Trades, Portfolio), Steven Cohen (Trades, Portfolio), Joel Greenblatt (Trades, Portfolio), Ray Dalio (Trades, Portfolio), Paul Tudor Jones (Trades, Portfolio) and David Dreman (Trades, Portfolio) have shares of Alcoa in their portfolios.

Alcoa sold for $9 per share Monday.

Romick acquired a 2,636,450-share stake in Esterline Technologies (ESL, Financial), a Bellevue, Washington-based producer of specialty products for the aerospace, defense, gaming and medical industries, for an average price of $85.12 per share. The acquisition had a 2.03% impact on Romick’s portfolio.

Esterline Technologies has a market cap of $2.51 billion and an enterprise value of $3.25 billion. It has a P/E of 46.9, a forward P/E of 15.1, a P/B of 1.6 and a P/S of 1.9. GuruFocus has given Esterline Technologies a Financial Strength rating of 8/10 and a Profitability and Growth rating of 7/10.

First Pacific Advisors (Trades, Portfolio), Michael Dell (Trades, Portfolio), Jim Simons (Trades, Portfolio), Robert Olstein (Trades, Portfolio), PRIMECAP Management (Trades, Portfolio) and Steven Cohen (Trades, Portfolio) have shares of Esterline Technologies in their portfolios.

Esterline Technologies sold for $84.85 per share Monday.

Romick sold his 1,478,715-share stake in Sulzer AG (SUN, Financial), a Swiss industrial engineering and manufacturing company, for an average price of CHF98.23 (about $99.81 in U.S. currency) per share. The transaction had a -1.46% impact on Romick’s portfolio.

Sulzer has a market cap of $3.38 billion and an enterprise value of $2.8 billion. It has a P/E of 12.4, a forward P/E of 28.4, a P/B of 1.6 and a P/S of 1.1. GuruFocus has given Sulzer a Financial Strength rating of 4/10 and a Profitability and Growth rating of 5/10.

Oakmark Intl Small Cap (Trades, Portfolio) has shares of Sulzer in its portfolio.

On Monday Sulzer sold for CHF98.15 (roughly $99.74 in American dollars) per share.

To view the portfolios of more gurus, visit the List of Gurus page. Not a premium member of GuruFocus? Try it free for 7 days.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.